ABSTRACT

Cancer as such does not impact distribution of antimicrobials; however, various pathophysiological changes in cancer patients may do so. Neutropenia, cachexia, hypoproteinemia, and effusions are common situations in cancer patients that may change the concentrations of antibiotics in blood and tissues. Such changes should be taken into account and dosage regimens adapted accordingly. As the therapeutic management of cancer patients becomes more complex, drug-drug interactions in oncology are of particular importance. Commonly used antibiotics that are most likely involved in drug-drug interactions are rifampin and its derivates, the macrolides erythromycin and clarithromycin, the fluoroquinolone ciprofloxacin and trimethoprim/sulfonamide combinations. Knowing the interaction profiles of individual agents and potential outcomes of the interaction allows healthcare providers to minimize the risk.